MedTrace Logo

The Diabetic Retinopathy Screening, Prevention and Control Program

NCT04240652 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500000

Last updated 2020-02-05

No results posted yet for this study

Summary

The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.

Conditions

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Guang Ning, MD,PHD · Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-05
Primary Completion
2038-06-05
Completion
2040-06-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240652 on ClinicalTrials.gov